Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing meropenem administration in the ICU – short six times vs prolonged three times daily
2024-520030-30-00Phase 3Authorised
- Sponsor
- Oslo University Hospital
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of meropenem in bacterial disease (2 arms), sponsored by Oslo University Hospital. Planned start Jan 2025; status: authorised.
02
Drugs
meropenem
03
Conditions
bacterial disease
Beyond the preview
Go deeper on 2024-520030-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520030-30-00.